

## CYSTIC FIBROSIS

Association between *Stenotrophomonas maltophilia* and lung function in cystic fibrosis

C H Goss, N Mayer-Hamblett, M L Aitken, G D Rubinfeld, B W Ramsey

Thorax 2004;59:955-959. doi: 10.1136/thx.2003.017707

See end of article for authors' affiliations

Correspondence to:  
Dr C H Goss, Assistant  
Professor of Medicine,  
University of Washington  
Medical Center, Campus  
Box 356522, 1959 NE  
Pacific, Seattle, WA  
98195, USA; goss@  
u.washington.edu

Received 23 October 2003  
Accepted 12 May 2004

Cystic fibrosis (CF) is one of the most common inherited fatal diseases in white ethnic groups with a reported incidence ranging from 1 in 2000 to 1 in 3200 live births.<sup>1</sup> With improved survival, physicians caring for these patients have witnessed the emergence of new pathogens in the CF lung including *Burkholderia cepacia*, *Stenotrophomonas maltophilia*, *Achromobacter xylosoxidans*, and *Mycobacterium avium* complex.<sup>2-4</sup> *Stenotrophomonas maltophilia* (previously *Pseudomonas* or *Xanthomonas maltophilia*) is a non-fermenting Gram-negative rod and one of the more prominent emerging pathogens in the CF airway with significant resistance to broad spectrum antibiotics, resulting in only limited treatment options. *S. maltophilia* has been isolated from a wide range of nosocomial sources including nebulisers and oxygen humidifier reservoirs.<sup>5</sup>

The importance of *S. maltophilia* colonisation in CF patients is still unclear. Three small single centre case-control studies have been performed which found no definitive evidence that *S. maltophilia* is associated with a worse prognosis.<sup>6-8</sup> A cohort study previously performed by our group using the CF Foundation National Patient Registry (CFF NPR) revealed that detection of *S. maltophilia* was not associated with worse short term (3 year) survival.<sup>9</sup> While the results of this study support the results from previous studies, evidence is still limited with regard to the effect of *S. maltophilia* on morbidity in CF patients, as assessed by surrogate markers such as decline in lung function. For this reason, we analysed data from the CFF NPR to investigate the effect of the organism on lung function.

## METHODS

## Study subjects

The CFF NPR contains data collected annually from participants at US CFF accredited centres.<sup>10</sup> We studied all patients in the NPR between January 1994 and December 1999 who were  $\geq 6$  years of age and had at least one pulmonary function measure by the end of the observation

**Background:** *Stenotrophomonas maltophilia* (SM) is a Gram-negative non-fermenting bacteria cultured from the sputum of patients with cystic fibrosis (CF). To date, no information is available regarding the effect of this organism on lung function in CF.

**Methods:** A cohort study was conducted to assess the effect of SM on lung function among CF patients aged  $\geq 6$  years in the CF Foundation National Patient Registry from 1994 to 1999. Repeated measures regression was used to assess the association between SM and lung function.

**Results:** The cohort consisted of 20 755 patients with median age at entry of 13.8 years and median follow up time of 3.8 years; 2739 patients (13%) were positive at least once for SM and 18 016 (87%) were never positive. After adjusting for sex, height and age, patients with SM had a mean forced expiratory volume in 1 second which was 0.09 l less (95% CI 0.05 to 0.14) than those without SM. The mean rate of decline associated with SM positivity was 0.025 l/year (95% CI 0.012 to 0.037) but, after adjusting for confounders (sex, height, weight, intravenous antibiotic courses, hospital admissions, pancreatic insufficiency, and *Pseudomonas aeruginosa* and *Burkholderia cepacia* status), the mean rate of decline decreased to 0.008 l/year (-0.008, 95% CI -0.019 to 0.003).

**Conclusions:** Although CF patients with SM have worse lung function at the time of positivity, no association was found between SM and increased rate of decline after controlling for confounders.

period. Patients under 6 years of age do not routinely have spirometry data in the NPR. The study was approved by the CFF and Institutional Review Board at the University of Washington, Seattle, WA.


## Study design

The design was a cohort study. Lung function was the primary outcome, as measured by forced expiratory volume in 1 second (FEV<sub>1</sub>) at most quarterly for each patient during each year of observation. Colonisation with *S. maltophilia* was recorded for each year of observation. Potential confounders of the relationship between *S. maltophilia* and lung function were also obtained over the observation period (weight, height, use of pancreatic enzymes, number of CF related hospital admissions, number of courses of home intravenous antibiotics, and presence of *Pseudomonas aeruginosa* and *Burkholderia cepacia*).

## Statistical analysis

Annual incidence and prevalence rates were computed. The incidence of newly diagnosed *S. maltophilia* cases was calculated for each year as the number of patients with their first detection of *S. maltophilia* divided by the total number of patients at risk for first detection of *S. maltophilia* in that year. The annual prevalence of *S. maltophilia* was calculated as the total number of cases of *S. maltophilia* each year divided by the total number of patients during that year. An overall *S. maltophilia* "case rate" was calculated for each centre as the total number of cases of *S. maltophilia* at that centre during the observation period divided by the total number of patients at that centre during the observation period.

Repeated measures linear regression<sup>11</sup> models were used to assess the effect of *S. maltophilia* on FEV<sub>1</sub> over time, with adjustment for potential confounders. Each patient contributed a maximum of four measurements each year of observation and the effect of time was captured in the model using age in years. Thus, in these models the effect of



**Figure 1** Incidence and prevalence of newly diagnosed *S maltophilia* cases during each year of observation in the cohort. Annual incidence (%) of new cases: number of new cases/number at risk. Annual prevalence (%) of current cases: number of cases/number at risk.


*S maltophilia* on lung function is interpreted as the average effect across age. Clinically relevant interactions were decided before assessment in the model. To ensure parsimonious models, only bacteria found to be significantly associated with clinical outcome in earlier models and the literature were assessed; thus, *Staphylococcus aureus* and *Haemophilus influenzae* culture status were not included in the current models. To assess the effect of first detection of *S maltophilia* during the study period on subsequent decline in lung function, the time since first detection of *S maltophilia* was included in the model and used to estimate rate of decline in FEV<sub>1</sub>. Time from first detection was zero when patients were negative for *S maltophilia* since the beginning of the observation period. For patients positive for *S maltophilia* during the observation period, time was calculated as number of years since first positive culture. To investigate the sensitivity of the results of the model to potential differences in detection of *S maltophilia* rates across centres, the final models were applied to subsets of the cohort who came from centres with different case rates and total number of *S maltophilia* cases. Observations with missing data were excluded from the analysis.

Analyses were performed with SAS 8.2 (SAS Institute Inc, Cary, NC) and Splus 6.1 (Insightful Corp, Seattle, WA). Overlapping research from our group is reported elsewhere.<sup>9</sup>

**RESULTS**

***S maltophilia* cohort characteristics**

A total of 20 755 patients aged 6 years and over were included in the cohort from all 176 CFF accredited centres (including pediatric CF centres, adult CF centres, and CF



**Figure 2** Distribution of *S maltophilia* case rates among the 176 centres.

centres comprised of both a pediatric and adult centre). The mean (SD) age at entry into the cohort was 16.1 (10.3) years (median 13.8 years), with a median follow up time of 3.8 years. 2739 patients (13%) were positive for *S maltophilia* at some point during follow up and 18 016 (87%) were never positive.

The mean (SD) age of the patients who were positive for *S maltophilia* during the first year in which it was detected during the study period was 18 (10.4) years. Nearly half were females and 55% were ΔF508 homozygous compared with 36% heterozygous for the ΔF508 mutation. The mean FEV<sub>1</sub> % predicted was 66.1% and, while 35% used home intravenous antibiotics during the year they were first detected with *S maltophilia* in the registry, 57% were hospitalised at least once. 63% of the patients were concurrently infected with *P aeruginosa* and only 5% with *B cepacia*.

***S maltophilia* detection rates**

There was only a slight increase in the incidence rate of first detected *S maltophilia* cases in the cohort over time, with the lowest incident rate of 2.7% in 1995 and the highest rate of 4.2% in 1999. The annual prevalence rate during each year of observation ranged from 3.2% in 1994 to 6.9% in 1999 (fig 1). The mean case rate of *S maltophilia* infection was 12.3% across the 176 centres, ranging from seven centres with no *S maltophilia* cases to one centre with a maximum rate of 38.6% (fig 2). There was no distinct association between the *S maltophilia* case rate and centre size (see fig S1 on the *Thorax* website at [www.thoraxjnl.com/supplemental](http://www.thoraxjnl.com/supplemental)). The distribution of the *S maltophilia* incidence and prevalence rates did not differ significantly by geographical region (p values 0.06 and 0.07, respectively; see fig S2 on the *Thorax* website at [www.thoraxjnl.com/supplemental](http://www.thoraxjnl.com/supplemental)).

**Association between *S maltophilia* and lung function**

*S maltophilia* was shown to be significantly negatively correlated with FEV<sub>1</sub> (model 1, table 1). Patients with *S maltophilia* had a mean FEV<sub>1</sub> 0.140 l (95% CI 0.112 to 0.167) less than patients without *S maltophilia* after adjusting for physiological confounders including sex, height, and age. The mean FEV<sub>1</sub> was 0.111 l less in females than in males (95% CI 0.090 to 0.132) and increased 0.034 l for every centimetre increase in height (95% CI 0.032 to 0.035). Age was independently associated with decreased lung function as measured by mean FEV<sub>1</sub> after adjusting for height and sex; each increase in age of 1 year was associated with a decrease in FEV<sub>1</sub> of 0.036 l (95% CI 0.033 to 0.039). There were no significant interactions between *S maltophilia* positivity and age, height, or sex. Thus, the association observed between FEV<sub>1</sub> and *S maltophilia* was similar across the different ages included in the cohort.

**Effect of *S maltophilia* on lung function decline**

To investigate the effect of *S maltophilia* on lung function decline after adjusting for age, sex, and height, time from first detection of *S maltophilia* during the study period was included in model 2 (table 2). The mean rate of decline after first detection of *S maltophilia* was 0.025 l (95% CI 0.012 to 0.037), indicating that *S maltophilia* has a modest impact on the decline in lung function without taking potential clinical confounders into account.

**Effect of *S maltophilia* on lung function after adjusting for clinical confounders**

Since the effect of *S maltophilia* on lung function and its decline may be confounded by important clinical variables, further modelling was done to include additional clinical characteristics (model 3, table 3). Genotype and pancreatic insufficiency were not found to be significantly related to

**Table 1** Model 1 investigating the association between *S maltophilia* and FEV<sub>1</sub> (in litres) after adjusting for physiological confounders

	Coefficient	95 % CI	p value
Intercept	-2.545	-2.752 to -2.337	<0.0001
Sex (female)	-0.111	-0.132 to -0.090	<0.0001
Height (cm)	0.033	0.032 to 0.035	<0.0001
Age (years)	-0.036	-0.039 to -0.033	<0.0001
Positive for <i>S maltophilia</i>	-0.140	-0.167 to -0.112	0.0001

FEV<sub>1</sub> in this model. For each kilogram increase in weight, FEV<sub>1</sub> increased by 0.036 l (95% CI 0.034 to 0.038). FEV<sub>1</sub> was significantly worse in patients who received intravenous antibiotics and/or were hospitalised. Patients who used two or more home intravenous antibiotic courses had a mean FEV<sub>1</sub> 0.235 l less than patients who did not use antibiotics (95% CI 0.211 to 0.256), and in patients with two or more hospital admissions the mean FEV<sub>1</sub> was 0.387 l less than patients not admitted to hospital (95% CI 0.367 to 0.407). *P aeruginosa* and *B cepacia* were shown to have a similar effect on FEV<sub>1</sub>. Patients infected with these organisms had a mean FEV<sub>1</sub> that was 0.149 l (95% CI 0.135 to 0.163) and 0.142 l (95% CI 0.103 to 0.181) less, respectively, than patients without these organisms. These two organisms contrast with the relatively mild impact of *S maltophilia* on FEV<sub>1</sub> of -0.035 l (95% CI -0.056 to -0.014). The time from first detection of *S maltophilia* was no longer significant in this model (-0.008 l, 95% CI -0.019 to 0.003).

#### Impact of repeated *S maltophilia* detection

Compared with *P aeruginosa*, repeated positivity for *S maltophilia* was not a common event (fig 3). Only 29% of the 2739 *S maltophilia* positive patients had *S maltophilia* detected for 2 years or more (not necessarily consecutive) during the observation period. In addition, only 11% of the *S maltophilia* positive patients had *S maltophilia* detected for more than 2 years, in contrast to data suggesting that over 80% of *P aeruginosa* positive patients have persistent positive cultures for 5 years or more. To assess the impact of more than 1 year of *S maltophilia* detection, the effect on the decline in lung function after the second year of positivity for *S maltophilia* was evaluated. After adjusting for height, age and sex, the mean rate of decline after the second detection of *S maltophilia* was 0.046 l (95% CI 0.021 to 0.071). However, after adjusting for additional confounders, the decline in lung function associated with 2 years or more of infection with *S maltophilia* was no longer significant.

#### Sensitivity of models to *S maltophilia* detection rates

To investigate the sensitivity of the models to potential *S maltophilia* detection differences between centres, the analyses were repeated in a subset of centres that had a

minimum *S maltophilia* case rate of 10% and at least 10 *S maltophilia* cases (representing 60% of the 20 755 patients in the cohort, 77% of the 2739 *S maltophilia* cases, and 43% of the 176 centres). Similar results were obtained from these analyses when compared with the entire cohort, with comparable effect sizes and significance of the coefficients. In particular, the time to first detection of *S maltophilia* remained non-significant. Further analyses were performed using subsets of data with different cut off values for the *S maltophilia* case rate and count and similar results were obtained, affirming the robustness of these findings.

#### DISCUSSION

*S maltophilia* continues to be a relatively common organism cultured from the sputum of patients with CF. Patients with *S maltophilia* are older, have mild to moderate decreases in lung function, and are commonly co-infected with *P aeruginosa*, as noted in earlier work.<sup>9</sup> Annual incidence rates of *S maltophilia* detected and reported in the CFF NPR did not change appreciably during the study period, which argues against a significant detection bias during the study period or a rapidly evolving outbreak in CF patients. However, we found significant variability of rates of *S maltophilia* detection at different centres and by region, with an increasing prevalence rate during the study period. On average, CF patients with *S maltophilia* had mildly decreased lung function after adjusting for age, sex, and height, and also had a mild increase in the rate of decline in lung function. The rate of lung function decline increased from 0.025 to 0.046 l/year after having *S maltophilia* detected in at least two separate or consecutive years. However, after adjusting for important confounders (age, sex, weight, height, pancreatic insufficiency, *P aeruginosa* and *B cepacia* colonisation, use of intravenous antibiotics), *S maltophilia* no longer had a significant effect on lung function decline. These findings were similar when only large centres with high case rates were analysed. The lack of evidence for a decline in lung function after adjusting for important confounders supports the contention that *S maltophilia* is not associated with a worse short term clinical outcome.<sup>9</sup>

In CF populations the prevalence rates of *S maltophilia* have varied depending on the population studied but, overall,

**Table 2** Model 2 investigating the association between time from first detection of *S maltophilia* during the observation period and FEV<sub>1</sub> (in litres) after adjusting for physiological confounders

	Coefficient	95 % CI	p value
Intercept	-2.547	-2.755 to -2.339	<0.0001
Sex (female)	-0.111	-0.132 to -0.090	<0.0001
Height (cm)	0.034	0.032 to 0.036	<0.0001
Age (years)	-0.036	-0.039 to -0.033	<0.0001
Positive for <i>S maltophilia</i>	-0.118	-0.143 to -0.093	<0.0001
Time from first detection of <i>S maltophilia</i>	-0.025	-0.037 to -0.012	0.0001


**Table 3** Model 3 investigating the association between time from first detection of *S maltophilia* during the observation period and FEV<sub>1</sub> (in litres) after adjusting for both physiological and clinical confounders

	Coefficient	95 % CI	p value
Intercept	-0.656	-0.828 to -0.484	<0.0001
Sex (female)	-0.049	-0.065 to -0.033	<0.0001
Height (cm)	0.013	0.011 to 0.015	<0.0001
Weight (kg)	0.036	0.034 to 0.038	<0.0001
Age (years)	-0.045	-0.047 to -0.043	<0.0001
Number of home IV antibiotic courses			
0	-	-	-
1	-0.113	-0.131 to -0.095	<0.0001
≥2	-0.235	-0.256 to -0.211	<0.0001
Total no of CF related hospital admissions			
0	-	-	-
1	-0.185	-0.199 to -0.171	<0.0001
≥2	-0.387	-0.407 to -0.367	<0.0001
Positive for <i>P aeruginosa</i>	-0.149	-0.163 to -0.135	<0.0001
Positive for <i>B cepacia</i>	-0.142	-0.181 to -0.103	<0.0001
Positive for <i>S maltophilia</i>	-0.035	-0.056 to -0.014	0.0014
Time from first detection of <i>S maltophilia</i>	-0.008	-0.019 to 0.003	0.1622

the prevalence appears to have increased over the last 15 years.<sup>12-14</sup> In one of the most comprehensive studies using microbiology of sputum samples from a study of aerosolised tobramycin in 595 patients at 69 CF centres in 1995-6, the prevalence of *S maltophilia* was 10.3%.<sup>14</sup> We now present data which support a relatively stable incidence rate from 1994 to 1999, despite fairly wide variation between centres. We cannot delineate whether this is due to differences in

culturing frequency or culturing techniques. A report by Shreve and colleagues noted that, by 1995, the majority of sites in the US followed the CFF consensus conference recommendations for quarterly cultures published in 1994, with all but two of 142 responding laboratories reporting growth of organisms like *S maltophilia* and *Achromobacter xylosoxidans*.<sup>15 16</sup> The relatively constant annual incidence rate seen in the current study argues against a sudden increase in detection or culturing techniques. Persistent *S maltophilia* infection (defined as three or more positive cultures in a 12 month period) is not a common event;<sup>8 17</sup> Demko and colleagues found persistent *S maltophilia* colonisation in only 11% of their cohort.<sup>8</sup> Episodic infection with *S maltophilia* (defined as only one positive culture out of a minimum of three cultures) has clearly been identified in the literature and was noted to be very common (50%).<sup>8</sup> Because the patients included in our study were denoted as positive if one or more cultures were positive during the year, one must be cautious in interpreting our results in comparison with other reports whose definitions have relied on the number of positive cultures over a discrete time period. We found that *S maltophilia* infection and detection (when based on positivity over a period of 1 year) is not a common event, with most patients in our cohort noted to be positive in only 1 year of the 6 year study period. In our population, only 29% of patients were positive for more than 1 year and 11% for more than 2 years. The isolation of *S maltophilia* in CF patients tends to be associated with more advanced disease.<sup>8 9 13 18</sup> Characteristics associated with *S maltophilia* detection include lower mean weight percentile, lower Shwachman-Kulczycki score, lower FEV<sub>1</sub> % predicted, more advanced age, oral quinolone antibiotic use, and long term antibiotic use.<sup>9 13 18 19</sup> Despite these results, nebulised tobramycin has not been conclusively associated with an increased risk of acquiring *S maltophilia*.<sup>18</sup> A significant proportion of patients in the current study had been hospitalised and received home intravenous antibiotics during the year of first detection of *S maltophilia* during the study period.

The clinical relevance of this increase in prevalence in *S maltophilia* remains unclear; however, the literature increasingly points to this pathogen acting as an intermittent coloniser of the CF airway without evidence of associated clinical decline.<sup>6 9</sup> Neither Gladman and colleagues<sup>6</sup> nor Karpati *et al*<sup>7</sup> found evidence of a clinical decline associated with *S maltophilia* colonisation in their studies. *S maltophilia* has been associated with a statistically significant decline in



**Figure 3** (A) Percentage of observation time (follow up time) during which annual culture results remain positive for patients who have been culture positive for *S maltophilia*, *P aeruginosa*, and *B cepacia*. (B) Number of years per patient that annual culture results are positive during the observation period (not necessarily consecutive) for *S maltophilia*, *P aeruginosa*, and *B cepacia*.

lung function (the absolute change was not noted)<sup>7</sup> and, in patients with severe pulmonary impairment, worse 2 year and possibly 5 year survival.<sup>8</sup> Formal survival modelling using data from the CFF NPR did not, however, corroborate the latter finding.<sup>9</sup> We have shown that *S maltophilia* is associated with a lower mean FEV<sub>1</sub> (0.092 l less) than in patients without *S maltophilia* after adjusting for height, sex, and age. However, the impact on mean lung function was much less than the effect of detecting *P aeruginosa* and *B cepacia* in the sputum of CF patients (0.035 l v 0.149 l and 0.142 l, respectively) after adjusting for important confounders. The rate of lung function decline after first detection of *S maltophilia* in this cohort was significant but small (0.025 l/year) after adjusting for physiological variables. Of some concern was the fact that this effect on lung function decline increased when evaluated after the second year of reported positivity for *S maltophilia* (0.046 l/year). However, this effect was not seen after adjusting for other important confounders.

Important limitations of these analyses relate to the assessment of *S maltophilia* status. Differences in the number of sputum samples requested, the specific organisms requested, and sputum culturing techniques may have changed over time, leading to misclassification of *S maltophilia* status and ascertainment bias. However, the effects of *S maltophilia* were noted to be similar when limited to large centres with high case rates. In our analyses, patients with a single positive culture per year are treated the same as patients with multiple positive cultures per year, thus limiting our ability to assess the effect of multiple infections within a given year. We also do not have specific data regarding compliance with the 1994 CFF consensus conference on microbiological procedures, nor were we able to control for treatment of *S maltophilia*. However, we were able to assess the effect of being repeatedly positive for *S maltophilia* over different years and found no evidence of an increased rate of lung function decline. Finally, the generalisability of the results is restricted to those patients included in the CFF NPR, but the NPR captures a significant proportion of the US CF population and an estimated 95% of all deaths in CF patients in the US.<sup>10</sup>

In conclusion, we have shown that *S maltophilia* is associated with lower mean lung function without evidence of an increased rate of decline in lung function after adjusting for confounders. *S maltophilia* remains a relatively common intermittent (not persistent) infection in CF, with relatively stable annual incidence rates during the period of study. *S maltophilia* is a pathogen, but its role in increasing the decline in lung function in CF is minimal, as suggested in this study. Further studies are needed to address treatment patterns for *S maltophilia* and the impact of such treatment on clinical outcome.

## ACKNOWLEDGEMENTS

The authors thank Preston Campbell III, Vice President for Medical Affairs, CF Foundation, Bruce Marshall, Director of Clinical Affairs, CF Foundation, Monica Brooks, CF Foundation, and the CF

community for their support of this project and for providing the CF Registry data.



Figures S1 and S2 are available online the *Thorax* website at [www.thoraxjnl.com/supplemental](http://www.thoraxjnl.com/supplemental).

## Authors' affiliations

**C H Goss, M L Aitken, G D Rubenfeld**, Department of Medicine, University of Washington Medical Center, Seattle, WA, USA  
**B W Ramsey, N Mayer-Hamblett**, Department of Pediatrics, University of Washington Medical Center, Seattle, WA, USA

Support: Leroy Matthew Physician Scientist, Cystic Fibrosis Foundation, The Firland Foundation.

## REFERENCES

- Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. *J Pediatr* 1998;**132**:589–95.
- Cystic Fibrosis Foundation. *Patient registry 2000 annual data report*. Bethesda, MD: Cystic Fibrosis Foundation, 2001:1–2.
- Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. *J Pediatr* 1985;**107**:382–7.
- Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. *Semin Respir Infect* 2002;**17**:47–56.
- Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with *Stenotrophomonas maltophilia*. *Clin Microbiol Rev* 1998;**11**:57–80.
- Gladman G, Connor PJ, Williams RF, et al. Controlled study of *Pseudomonas cepacia* and *Pseudomonas maltophilia* in cystic fibrosis. *Arch Dis Child* 1992;**67**:192–5.
- Karpati F, Malmborg AS, Alfredsson H, et al. Bacterial colonisation with *Xanthomonas maltophilia*: a retrospective study in a cystic fibrosis patient population. *Infection* 1994;**22**:258–63.
- Demko CA, Stern RC, Doershuk CF. *Stenotrophomonas maltophilia* in cystic fibrosis: incidence and prevalence. *Pediatr Pulmonol* 1998;**25**:304–8.
- Goss CH, Otto K, Aitken ML, et al. Detecting *Stenotrophomonas maltophilia* does not reduce survival of patients with cystic fibrosis. *Am J Respir Crit Care Med* 2002;**166**:356–61.
- Fitzsimmons SC. The changing epidemiology of cystic fibrosis. *J Pediatr* 1993;**122**:1–9.
- Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. *Biometrika* 1986;**73**:13–22.
- Bauernfeind A, Emminger G, Horl G, et al. Bacteriological effects of anti-*Pseudomonas aeruginosa* chemotherapy in cystic fibrosis. *Infection* 1987;**15**:403–6.
- Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of *Stenotrophomonas maltophilia* in cystic fibrosis patients. *Eur J Clin Microbiol Infect Dis* 1996;**15**:402–5.
- Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. *Clin Infect Dis* 1998;**27**:158–63.
- Shreve MR, Butler S, Kaplowitz HJ, et al. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. *J Clin Microbiol* 1999;**37**:753–7.
- Cystic Fibrosis Foundation. *Microbiology and infectious disease in cystic fibrosis. Concepts of care*. Rockville, MD: Cystic Fibrosis Foundation, 1994:1–26.
- Krzewinski JW, Nguyen CD, Foster JM, et al. Use of random amplified polymorphic DNA PCR to examine the epidemiology of *Stenotrophomonas maltophilia* and *Achromobacter (Alcaligenes) xylosoxidans* from patients with cystic fibrosis. *J Clin Microbiol* 2001;**39**:3597–602.
- Graff GR, Burns JL. Factors affecting the incidence of *Stenotrophomonas maltophilia* isolation in cystic fibrosis. *Chest* 2002;**121**:1754–60.
- Talmaciu I, Varlotta L, Mortensen J, et al. Risk factors for emergence of *Stenotrophomonas maltophilia* in cystic fibrosis. *Pediatr Pulmonol* 2000;**30**:10–5.